Most Read News

It was a relief rally in the first week of March, although the bounce was more pronounced in mid and small caps

FPIs net sold $(2,835) Million in Indian equities; marking one of the heavies weeks of FPI selling in recent months

According to Jerome Powell, the Fed may pause on rates for now, and await clarity on Trump Tariffs

Edelweiss Low Duration Fund is a smart saving fund, better than a bank account, but lower on risk than long duration debt

IndusInd Bank is the only stock that hits a 52-week low in Sensex and Nifty

The company also informed the bourses that the estimated investment in these projects shall be approximately up to ₹49,000 Crore.

The NIFTY Pharma index closed the week with a 2.9% gain. Its performance was inline with that of NIFTY 50. In addition to a broadbased rally, strong performance from Biocon (+10.3%), Glenmark (+9.8%), and Laurus Labs (+8.3%) contributed to its performance. Concerns over tariffs from US on Indian pharmaceutical exports are the key headwind for the space. 

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

The market correction was relatively subdued, but the good news is the positive bounce in mid-caps and small caps

The company stated that its Indian operations produced 23.32 Lakh tonnes, up by 13% year-on-year against 20.59 Lakh tonnes.